202 related articles for article (PubMed ID: 33358592)
21. Pancreatic NETs: where do we stand now?
Faivre S; Castellano D; Strosberg J; González E; Salazar R
Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.
Berardi R; Torniai M; Pusceddu S; Spada F; Ibrahim T; Brizzi MP; Antonuzzo L; Ferolla P; Panzuto F; Silvestris N; Partelli S; Ferretti B; Freddari F; Gucciardino C; Testa E; Concas L; Murgioni S; Bongiovanni A; Zichi C; Riva N; Rinzivillo M; Brunetti O; Giustini L; Di Costanzo F; Delle Fave G; Fazio N; De Braud F; Falconi M; Cascinu S
Cancer Med; 2017 Jul; 6(7):1493-1499. PubMed ID: 28547856
[TBL] [Abstract][Full Text] [Related]
23. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
[TBL] [Abstract][Full Text] [Related]
24. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC
Ann Oncol; 2017 Jun; 28(6):1309-1315. PubMed ID: 28327907
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
Douangprachanh S; Joo HJ; Park HM; Han N; Jang HY; Koh YH; Kim TH; Han SS; Park SJ; Lee WJ; Woo SM; Chun JW
Korean J Intern Med; 2022 Nov; 37(6):1216-1222. PubMed ID: 36375489
[TBL] [Abstract][Full Text] [Related]
26. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Chatzellis E; Angelousi A; Daskalakis K; Tsoli M; Alexandraki KI; Wachuła E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G
Neuroendocrinology; 2019; 109(4):333-345. PubMed ID: 31167197
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
28. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
[TBL] [Abstract][Full Text] [Related]
29. O
Watanabe H; Yamazaki Y; Fujishima F; Izumi K; Imamura M; Hijioka S; Toriyama K; Yatabe Y; Kudo A; Motoi F; Unno M; Sasano H
BMC Cancer; 2020 Dec; 20(1):1195. PubMed ID: 33287738
[TBL] [Abstract][Full Text] [Related]
30. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
31. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.
Ito T; Okusaka T; Ikeda M; Igarashi H; Morizane C; Nakachi K; Tajima T; Kasuga A; Fujita Y; Furuse J
Jpn J Clin Oncol; 2012 Oct; 42(10):903-11. PubMed ID: 22859827
[TBL] [Abstract][Full Text] [Related]
32. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Kulke MH; Hornick JL; Frauenhoffer C; Hooshmand S; Ryan DP; Enzinger PC; Meyerhardt JA; Clark JW; Stuart K; Fuchs CS; Redston MS
Clin Cancer Res; 2009 Jan; 15(1):338-45. PubMed ID: 19118063
[TBL] [Abstract][Full Text] [Related]
33. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
Wang W; Zhang Y; Peng Y; Jin KZ; Li YL; Liang Y; Tan HY; Yu XJ; Zhou ZW; Chen J
Neuroendocrinology; 2021; 111(8):752-763. PubMed ID: 32668427
[TBL] [Abstract][Full Text] [Related]
34. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
35. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Al-Toubah T; Morse B; Strosberg J
Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.
Lee KJ; Cho JH; Lee SH; Song SY; Lee KH; Jeong S; Ryu JK; Woo SM; Bang S; Lee JK; Lee TH; Paik WH; Kim YT; Lee WJ
Cancer Chemother Pharmacol; 2017 Oct; 80(4):799-805. PubMed ID: 28884280
[TBL] [Abstract][Full Text] [Related]
37. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL; Graham NT; Catalano PJ; Nimeiri HS; Fisher GA; Longacre TA; Suarez CJ; Martin BA; Yao JC; Kulke MH; Hendifar AE; Shanks JC; Shah MH; Zalupski MM; Schmulbach EL; Reidy-Lagunes DL; Strosberg JR; O'Dwyer PJ; Benson AB
J Clin Oncol; 2023 Mar; 41(7):1359-1369. PubMed ID: 36260828
[TBL] [Abstract][Full Text] [Related]
38. Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors.
De Rycke O; Walter T; Perrier M; Hentic O; Lombard-Bohas C; Coriat R; Cadiot G; Couvelard A; Ruszniewski P; Cros J; de Mestier L
Endocr Relat Cancer; 2021 Jun; 28(7):457-466. PubMed ID: 33979778
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
